Equities

Guardian Pharmacy Services, Inc.

  • Add to watchlist
  • Add to portfolio
  • Add an alert
GRDN:NYQ

Guardian Pharmacy Services, Inc.

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (USD)39.47
  • Today's Change-0.21 / -0.53%
  • Shares traded426.03k
  • 1 Year change+61.96%
  • Beta--
Data delayed at least 15 minutes, as of Oct 16 2026 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Oct-25
  • 16-Jul-26
  • 20-Aug-26
  • 17-Sep-26
  • 15-Oct-26
Select bar for recommendation details.
Recommendations15-Oct-26
Buy4
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Guardian Pharmacy Services Inc have a median target of 50.00, with a high estimate of 52.00 and a low estimate of 40.58. The median estimate represents a 26.68% increase from the last price of 39.47.
High31.7%52.00
Med26.7%50.00
Low2.8%40.58

Earnings history & estimates in USD

On Aug 06, 2026, Guardian Pharmacy Services Inc reported 2nd quarter 2026 earnings of 0.34 per share. This result exceeded the 0.270 consensus of the 5 analysts covering the company and exceeded last year's 2nd quarter results by 0.20.
The next earnings announcement is expected on Nov 09, 2026.
Average growth rate+38.17%
Guardian Pharmacy Services Inc reported annual 2025 earnings of 0.78 per share on Mar 11, 2026.
More ▼

Revenue history & estimates in USD

Guardian Pharmacy Services Inc had 2nd quarter 2026 revenues of 351.77m. This bettered the 340.05m consensus of the 5 analysts covering the company. This was 6.82% above the prior year's 2nd quarter results.
Average growth rate+1.03%
Guardian Pharmacy Services Inc had revenues for the full year 2025 of 1.45bn. This was 17.93% above the prior year's results.
Average growth rate+17.93%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.